Doris Wilflingseder
Overview
Explore the profile of Doris Wilflingseder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
1656
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sahanic S, Hilbe R, Dunser C, Tymoszuk P, Loffler-Ragg J, Rieder D, et al.
Heliyon
. 2023 Nov;
9(11):e21893.
PMID: 38034686
Background: Toll-like receptors (TLRs) play a pivotal role in the immunologic response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Exaggerated inflammatory response of innate immune cells, however, may...
12.
Zaderer V, Abd El Halim H, Wyremblewsky A, Lupoli G, Dachert C, Muenchhoff M, et al.
Front Immunol
. 2023 Nov;
14:1258268.
PMID: 37915577
Introduction: To explore whether the reported lower pathogenicity in infected individuals of variant of concern (VoC) Omicron and its current subvariants compared to VoC Delta may be related to fundamental...
13.
Rauchenwald T, Handle F, Connolly C, Degen A, Seifarth C, Hermann M, et al.
Inflamm Regen
. 2023 Oct;
43(1):53.
PMID: 37904253
Background: Chronic non-healing wounds pose a global health challenge. Under optimized conditions, skin wounds heal by the formation of scar tissue. However, deregulated cell activation leads to persistent inflammation and...
14.
Caloni F, Cazzaniga A, Gutleb A, Kandarova H, Ranaldi G, Rashidi H, et al.
ALTEX
. 2023 Oct;
40(4):694-696.
PMID: 37889189
No abstract available.
15.
Diem G, Dichtl S, Zaderer V, Lass-Florl C, Reindl M, Lupoli G, et al.
Microbiol Spectr
. 2023 Aug;
:e0179323.
PMID: 37551989
Currently, SARS-CoV-2 Omicron BA.5 subvariants BF.7 and BQ.1.1 are rapidly emerging worldwide. To evaluate the SARS-CoV-2-neutralizing capacity of sera and saliva from triple vaccinated individuals, either boosted with an adapted...
16.
Diem G, Jager M, Dichtl S, Bauer A, Lass-Florl C, Reindl M, et al.
Microbiol Spectr
. 2023 Apr;
11(3):e0516322.
PMID: 37098903
Rising breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.4/5 led to the performance of various studies investigating systemic immunity and neutralizing antibodies in sera, but mucosal...
17.
Dichtl S, Diem G, Jager M, Zaderer V, Lupoli G, Dachert C, et al.
Antiviral Res
. 2023 Mar;
213:105581.
PMID: 36965526
The identification of the SARS-CoV-2 Omicron variants BA.4/BA.5, BF.7 and BQ.1.1 immediately raised concerns regarding the efficacy of currently used monoclonal antibody therapies. Here we examined the activity of monoclonal...
18.
Zaderer V, Dichtl S, Posch W, Abiatari I, Bonn G, Jakschitz T, et al.
Respir Res
. 2023 Mar;
24(1):88.
PMID: 36949547
New SARS-CoV-2 variants of concern (VOCs) and waning immunity illustrate that quick and easy-to-use agents are needed to prevent infection. To protect from viral transmission and subsequent inflammatory reactions, we...
19.
Jager M, Diem G, Sahanic S, Fux V, Griesmacher A, Lass-Florl C, et al.
J Infect Dis
. 2023 Mar;
228(2):160-168.
PMID: 36869832
Background: The emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants BA.1, BA.2, and BA.4/5 demonstrate higher transmission and infection rates than previous variants of concern. To evaluate effectiveness...
20.
Zaderer V, Dichtl S, Bellmann-Weiler R, Lass-Florl C, Posch W, Wilflingseder D
Respir Res
. 2023 Jan;
24(1):27.
PMID: 36694236
No abstract available.